Advanced dual-action weight loss therapy Tirzepatide is the next generation of GLP-1 weight loss targeting two metabolic pathways simultaneously for greater weight loss potential
Seek medical advice if you experience: Severe or persistent insomnia lasting more than 23 weeks, particularly if it significantly impairs daytime functioning Excessive daytime sleepiness that interferes with daily activities or poses safety risks (e.g., whilst driving) Sleep disturbances accompanied by severe gastrointestinal symptoms such as persistent vomiting, severe abdominal pain, or signs of dehydration Severe, persistent abdominal pain that may radiate to your back, especially if accompanied by vomiting, fever or jaundice (yellowing of skin/eyes), as these could indicate pancreatitis or gallbladder disease requiring urgent medical attention Mood changes including low mood, anxiety, or irritability that may be related to poor sleep quality Symptoms suggestive of sleep apnoea , such as loud snoring, witnessed breathing pauses, or morning headachesthough these should improve with weight loss Consider contacting your healthcare provider if: Sleep problems persist beyond the initial 48 week adjustment period Sleep disturbances worsen following dose escalation and do not improve within 2 weeks You are considering stopping Wegovy due to sleep-related concerns You require guidance on managing sleep issues alongside other medications Your GP may recommend adjustments to your Wegovy dosing schedule, additional investigations to exclude other causes of sleep disturbance, or referral to specialist services if appropriate
Peptides can be used through topical serums, hair products, supplements, or advanced treatments, often working best as part of a broader hair health strategy that improves scalp environment and follicle function
If intensive blood glucose management can be achieved without hypoglycemia, it may be considered for certain individuals, such as those in critical care who have undergone surgery
